Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study
- PMID: 29736166
- PMCID: PMC5875045
- DOI: 10.1155/2018/1794524
Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study
Abstract
Aim: To investigate the role of maximum tumour diameter (D-max) reduction rate at CT examination in predicting histopathological tumour regression grade (TRG according to the Becker grade), after neoadjuvant chemotherapy (NAC), in patients with resectable advanced gastric cancer (AGC).
Materials and methods: Eighty-six patients (53 M, mean age 62.1 years) with resectable AGC (≥T3 or N+), treated with NAC and radical surgery, were enrolled from 5 centres of the Italian Research Group for Gastric Cancer (GIRCG). Staging and restaging CT and histological results were retrospectively reviewed. CT examinations were contrast enhanced, and the stomach was previously distended. The D-max was measured using 2D software and compared with Becker TRG. Statistical data were obtained using "R" software.
Results: The interobserver agreement was good/very good. Becker TRG was predicted by CT with a sensitivity and specificity, respectively, of 97.3% and 90.9% for Becker 1 (D-max reduction rate > 65.1%), 76.4% and 80% for Becker 3 (D-max reduction rate < 29.9%), and 70.8% and 83.9% for Becker 2. Correlation between radiological and histological D-max measurements was strongly confirmed by the correlation index (c.i.= 0.829).
Conclusions: D-max reduction rate in AGC patients may be helpful as a simple and reproducible radiological index in predicting TRG after NAC.
Figures












Similar articles
-
Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Quant Imaging Med Surg. 2021 Jun;11(6):2376-2387. doi: 10.21037/qims-20-683. Quant Imaging Med Surg. 2021. PMID: 34079708 Free PMC article.
-
Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer.Abdom Imaging. 2009 Jul;34(4):430-40. doi: 10.1007/s00261-008-9420-8. Abdom Imaging. 2009. PMID: 18546037 Clinical Trial.
-
Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes.Hum Pathol. 2021 Oct;116:94-101. doi: 10.1016/j.humpath.2021.07.003. Epub 2021 Jul 17. Hum Pathol. 2021. PMID: 34284051
-
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.Acta Oncol. 2017 Mar;56(3):391-397. doi: 10.1080/0284186X.2016.1256497. Epub 2016 Nov 25. Acta Oncol. 2017. PMID: 27885876
-
CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy.Front Oncol. 2022 Feb 25;12:758863. doi: 10.3389/fonc.2022.758863. eCollection 2022. Front Oncol. 2022. PMID: 35280802 Free PMC article.
Cited by
-
Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy.Chin J Cancer Res. 2021 Aug 31;33(4):447-456. doi: 10.21147/j.issn.1000-9604.2021.04.02. Chin J Cancer Res. 2021. PMID: 34584370 Free PMC article.
-
The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.BMC Cancer. 2023 Nov 27;23(1):1157. doi: 10.1186/s12885-023-11619-2. BMC Cancer. 2023. PMID: 38012547 Free PMC article.
-
Gastrointestinal stromal tumors (GIST): a proposal of a "CT-based predictive model of Miettinen index" in predicting the risk of malignancy.Abdom Radiol (NY). 2020 Oct;45(10):2989-2996. doi: 10.1007/s00261-019-02209-7. Abdom Radiol (NY). 2020. PMID: 31506758
-
Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.Abdom Radiol (NY). 2023 Dec;48(12):3661-3676. doi: 10.1007/s00261-023-04046-1. Epub 2023 Oct 3. Abdom Radiol (NY). 2023. PMID: 37787962 Review.
-
Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).Quant Imaging Med Surg. 2021 Jun;11(6):2376-2387. doi: 10.21037/qims-20-683. Quant Imaging Med Surg. 2021. PMID: 34079708 Free PMC article.
References
-
- Amin M. B., Edge S., Greene F., et al. AJCC Cancer Staging Manual. 8th. New York, NY, USA: Springer; 2017.
LinkOut - more resources
Full Text Sources
Other Literature Sources